anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Energy expenditure (EE) in patients with aneurysmal subarachnoid hemorrhage (SAH) may differ from other intracranial pathologies, such as intracerebral hemorrhage (ICH) or traumatic brain injury (TBI), due to an activation of the sympathetic nervous system. Indirect calorimetry (IC) is recommended, but is not always available. We study EE, catabolism, and metabolic stress in patients with SAH, TBI, ICH, and sepsis as controls.
METHODS: A prospective observational study was conducted in the intensive care units of the University Medical Center Hamburg-Eppendorf, Germany. IC was used to measure EE on days 2-3, 5-7, and 10-15 post-admission. Urinary catecholamines, metabolites, and urine urea were also measured. Statistical analysis included t-tests, Chi-square tests, and generalized mixed models.
RESULTS: We included 110 patients-43 SAH patients (13 with the surgical securing of the aneurysm and 30 with coil embolization of the aneurysm), 22 TBI patients, 23 ICH patients, and 22 controls. The generalized linear mixed model analysis for groups and timepoints including age, height, and weight as covariates revealed a significantly lower EE at timepoint 1 for ICH versus SAH-interventional (p = 0.003) and versus the control (p = 0.004), as well as at timepoint 2 for ICH versus SAH-interventional (p = 0.002) and versus SAH-surgical (p = 0.013) with a lower EE in ICH patients. No significant differences between groups were found for EE at the other timepoints, or concerning urine urea and measurements of catecholamines in urine.
CONCLUSIONS: In patients with SAH, ICH, and TBI, no meaningful differences in EE were detected compared to septic critically ill patients, except for a lower EE in ICH patients in the early phase.
Stroke commonly known as Cerebro-Vascular Accident (CVA), is stated as a sudden commencement of neurological discrepancy which is attributable to a pivotal vascular basis. In modest words, it is a "brain attack", which occurs when the brain fails to get adequate blood circulation, as a result, brain cells do not get a sufficient amount of oxygen, and cells start dying ultimately. Brunnstrom movement therapy uses reflexes to develop movement behavior through sensory stimulation, in order to inhibit spasticity and movement retraining to enhance recovery. Mirror therapy (MT) in stroke patients involves performing unimpaired limb movements while observing there reflection of the mirror overlapping the impaired limb, creating a visual illusion of increased movement capacity in the impaired limb.

In previous researches, various conventional and contemporary approaches such as Brunnstrom, and Mirror therapy have been used to rehabilitate the hand after stroke in clinical settings. Previous literature was focus on digital and other conventional methods. However, despite a revolution in the number of therapeutic protocols, evidence of efficacy remains limited. Both BHM and MT have been studied separately to evaluate their respective effectiveness. However, no study has been found comparing the two protocols exclusively for hand motor recovery.
PROBLEM TO BE SOLVED: To obtain the subject antibiotics exhibiting excellent antibacterial activities against gram-positive bacteria and other multiple medicine-resistant bacterial, low in toxicity, and useful as excellent antibacterial agents. SOLUTION: Compounds of formula I (R is a group of formula II for tetromycin C1, a group of formula III for tetromycin C2, etc.) or their salts. The tetromycin C1 has the following natures. Appearance: colorless acicular crystal; molecular formula: C50 H64 O14 ; melting point: 190-193 deg.C; specific rotation: [α]D<25> =-26.0 deg. (c 0.53 in acetone), etc. The compound of formula I is obtained by culturing a fungus belonging to the genus Streptomyces and capable of producing the compound of formula I [preferably Streptomyces SP-MK 67-CF9 (FFRM P-14609), etc.] in a culture medium, and subsequently collecting the compound of formula I from the culture product. The producing fungus is preferably inoculated in a nutritive culture medium and subsequently aerobically subjected to a shaking culture at approximately 25 deg.C.  The component of formula I is collected e.g. by an extraction method using water and a miscible solvent, a gel filtration method, etc.
Primary prevention of cardiovascular diseases is a priority in public health policy of developed and developing countries. The fundamental strategy consists in identifying people in a high risk situation in which preventive measures are effective and efficient. However, specificity and sensitivity of risk equations are modest, which means that approximately 50% of the patients who are likely to develop a vascular event and would benefit from preventive measures are not considered at high risk. While 30% of the subjects considered at risk don't really benefit from preventive measures. Moreover, decisions which imply thousands of people and can determine drug treatment indications are taken every day in primary care centers. These decisions are based mostly on the result of estimations about the probability to develop a vascular disease in 10 years. Improvement of these predictions in our country will have an immediate, clinical and welfare impact and a short term public health effect.

The purpose of this study is to analyze if ankle-brachial index (ABI), measures of arterial stiffness, postprandial glucose, glycosylated hemoglobin, self-measured blood pressure and presence of comorbidity are independently associated to incidence of vascular events and whether they can improve the predictive capacity of current risk equations in the intermediate-risk population.
The invention discloses a preparation method of a deferasirox derivative. The preparation process comprising optimal reactant usage amount, reaction temperatures, reaction time, reaction steps and the like is determined via a large quantity of experimental screening. The whole preparation process is strong in maneuverability, high in preparation efficiency and low in production cost; and especially, the total yield can reach more than 30%. Compared with the prior art that the total yield is only 14% or so, the preparation process disclosed by the invention has a good technical effect. In addition, the whole preparation process is convenient for purification, thereby overcoming the technical defect of complicated separation and purification in the prior art and having the relatively high production efficiency. Thus, the industrial mass production can be realized.
A blood-sugar reducing agent is obtained from urine by subjecting the urine to autolysis and separating the active substance by adsorption, salting out or dialysis.  Autolysis is effected by allowing the urine to stand under toluene or allowing it to stand, after concentration, e.g. to a tenth of its volume, at low temperature without the addition of a disinfecting agent. Adsorption is effected by addition of agents such as frankonite, fullers' earth, &c. or the adsorbent may be formed in the solution by addition of the soluble salt of a water insoluble acid, e.g. sodium urate or silicate and precipitation of the insoluble acid. Salting out may be effected by addition of ammonium sulphate or common salt.  Extraction of the active substance is effected with ammonia or dilute alkali lye.
The invention discloses a monoclonal antibody specifically recognizing CLDN18.2, and related products, methods and uses thereof, wherein the amino acid sequences of CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and the amino acid sequences of CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO. 9, SEQ ID NO. 10 and SEQ ID NO. 11, and experiments prove that CAR-T cells prepared based on the monoclonal antibody can kill cells expressing CLDN18.2 efficiently and specifically, and have good clinical application prospects.
The invention relates to powdery compositions for temporarily shaping human hair, containing between 50 and 90 wt. % of water, between 0.5 wt. % and 10 wt. % of at least one other liquid having a boiling point higher than 150°C at a pressure of 1013 mbar, at least one starch substituted with carboxy-(C1 bis C4) alkyl groups, and metal oxide particles that have been coated on the surface with organic groups containing fluorine. Said powdery compositions, when applied to hair, enable an excellent hairstyle and shine. The powdery compositions can easily be applied to hair. By mechanically manipulating the hair covered with the powdery compositions, the cosmetic active substances are released in a targeted manner exclusively on the areas of the hair to be shaped.
Process for the preparation of d,l-5-methyltetrahydrofolic acid and its salts of the formula 1 in which X is hydrogen, an alkali metal or the equivalent of an alkaline earth metal, by reduction of folic acid with NaBH4 and methylation of the tetrahydrofolic acid obtained with aqueous solutions of formaldehyde and sodium borohydride in an inert gas atmosphere. The process is simple and can be carried out without separation of intermediates while carrying out the process steps successively in the same reaction vessel. The final products are obtained in a yield of more than 80%, relative to folic acid employed, in a purity of more than 99%. The compounds of the formula I obtained are non-toxic, stable at physiological pH and suitable for the preparation of liquid or solid pharmaceutical compositions for any type of application in human therapy. Such compositions exhibit haematopoietic action, hepatoprotective and antineoplastic action. <IMAGE>
Two randomized, double-blind studies were conducted in adults. In the first trial, 103 patients with active mild-to-moderate ulcerative colitis with sigmoidoscopy findings of friable or spontaneously bleeding mucosa were randomized and treated with balsalazide 6.75 g/day or balsalazide 2.25 g/day. The primary efficacy endpoint was reduction of rectal bleeding and improvement of at least one of the other assessed symptoms (stool frequency, patient functional assessment, abdominal pain, sigmoidoscopic grade, and physician’s global assessment [PGA]). Outcome assessment for rectal bleeding at each interim period (week 2, 4, and 8) encompassed a 4-day period (96 hours). Results demonstrated a statistically significant difference between high and low doses of balsalazide (Figure 1).

Figure 1: Percentage of Patients Improved at 8 weeks

A second study, conducted in Europe, confirmed findings of symptomatic improvement.
Patients are enrolled in one of two study groups. The treatment group consists of HIV-1 seropositive patients with hemophilia A or B who are protease-inhibitor naive. The laboratory control group consists of HIV-1 seropositive patients with hemophilia A who are on a stable, triple-combination antiretroviral regimen. Patients in the treatment group receive indinavir sulfate plus two of the following NRTIs: zidovudine (ZDV), didanosine (ddI), zalcitabine (ddC), stavudine (d4T), or lamivudine (3TC). Patients in the treatment group preferably are naive to one or both of the NRTIs. Patients in the laboratory control group continue on their stable triple antiretroviral regimen consisting of a protease inhibitor plus two NRTIs. Patients in the control group are not provided antiretroviral medications as part of this study. Patients in the treatment group are evaluated by physical examination, safety laboratory tests, CD4 cell counts, and viral load on Day 1 and at Weeks 2, 4, 8, and 12 and then every 8 weeks through Week 52. Patients in the control group are evaluated by physical examination, safety laboratory tests, CD4 cell counts, and viral load on Day -1 and at Week 12. All patients receive their usual factor concentrate infusion over a 10-minute period on Day -1 and at Week 12 to estimate factor VIII (or IX) recovery and half-life. Blood samples are taken prior to infusion and 30 minutes and 1, 3, 6, 9, 12, and 24 hours after infusion. All patients are required to keep a daily log documenting bleeding episodes and use of factor VIII (or IX) throughout the study.
The present invention relates to a health eye hood made of a Chinese medicine composition, preparation and a use method thereof. The health eye hood is made of a Chinese medicine composition comprising the components by the weight proportion: 18 to 24% of mulberry, 9 to 15% of cicada slough, 20 to 30% of argy wormwood leaf, 18.5 to 24% of feverfew and 18.5 to 24% of shave grass which are pulverized and mixed into the medicine which is put in ellipse cloth bags made of cotton cloth to become the eye hood. The eye hood is used during rests and sleeps, and medicine in the eye hood can be used for effectively strengthening blood circulation in various capillary vessels of the eye so as to strengthen oxygen supply for various muscles of the eye. The fatigue muscles of the eye can be well improved, lacrimal gland tissue can be lifted, and a cerebrum sleep state can be promoted and regulated. Thus, sleep quality can be effectively enhanced. The Chinese medicine composition of the present invention has no side effect on a human body and has a certain therapeutic effect on pseudomyopia. The product of the present invention has the advantages of convenient use, comfort and simplicity and is used during eye use breaks during work, study, etc. During sleep, the eye hood has a particular use effect and is particularly suitable for people who excessively use the eye and people with great working pressure.
This study is a randomized controlled trial conducted at a single center with raters blinded to the intervention. We will look at the clinical effect of MARS-PD, consisting of 16 interventions over an 8-week period, in 88 individuals with Parkinson's disease. Patients will be assigned to either the experimental (n=44) or control (n=44) groups at random. he experimental group will receive the MARS intervention, while the control group will receive usual care only. The treatment duration is 8 weeks, followed by a 12-week follow-up. The primary outcome is the change in MDS-UPDRS Part III (Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III) score from baseline to 8 weeks. Secondary outcomes include assessments such as MDS-UPDRS, International Physical Activity Questionnaire Short Form, Parkinson Self Questionnaire, Parkinson's Disease Sleep Scale, Timed Up and Go test, GAITRite metrics, Functional Near-Infrared Spectroscopy measurements, smart band results, gut microbiome composition and diversity, and iris connective tissue texture.
The Integrated ID/MOUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating OUD, resolving the sentinel infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and MOUD providers.
The method with the traditional Chinese medicine health care product for improving sleep effect is manufactured the invention discloses a kind of, is comprised the following steps：S1. spina date seed, wilsonii, gynostemma pentaphylla, chrysanthemum, Asian puccoon, sweet osmanthus, Radix Angelicae Sinensis are put into pure water and soaked;S2. separately take the root of kudzu vine, coptis root, the fruit of Chinese magnoliavine, matrimony vine, Poria cocos, mulberry fruit to be put into pure water to soak;S3. the medicinal material taking-up finished will be soaked in step S1,2000ml pure water is rejoined and boils rear small fire decoction 1 hour, be filtrated to get Chinese medicine residue and filtrate；S4. the medicinal material obtained in step S2 is added in the filtrate obtained into step S3, pure water is added to 2000ml, rear small fire is boiled and decocts 2 hours, be filtrated to get Chinese medicine liquid；S5. the Chinese medicinal liquid concentrating obtained in step S4 to 1000ml is obtained into oral liquid part；S6. the Chinese medicine residue obtained in step S3 is dried and is ground into powder；S7. the powder and essential oil obtained in step S6 is added into facial mask auxiliary material, externally dressing part is uniformly mixing to obtain.
A combination method of broad-spectrum antibacterial tablets for eliminating skin acne, purging fire and removing toxin and a manufacturing process thereof are as follows: taking appropriate amount of mulberry leaf, purple perilla, chrysanthemum, polygonatum, poria cocos, fructus amomi, honeysuckle and syrup, cleaning the raw materials with the formula amount of 50%, adding water, extracting for three times, pressurizing and filtering the separated extract into thick paste for later use. Cleaning other raw materials, drying, and pulverizing into dry powder. Finally, the thick paste, the dry powder and the starch are evenly mixed, dried, crushed into dry powder, added with proper magnesium stearate, granulated and tabletted to obtain the finished product. The product can be taken for a long time to purge fire and detoxify toxin, has broad-spectrum antibacterial property, and can nourish and moisten skin, not only can effectively eliminate skin acne, but also has no toxic or side effect, and achieves the beautifying effect. And has effects of enhancing immunity and delaying aging. The invention has simple manufacturing process and lower cost.
For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
BACKGROUND: Onychocryptosis is a nail deformity that occurs when the side of the nail grows into soft tissue, which causes pain, sepsis and the formation of granulation. The aim of the study was to evaluate and compare different levels of kinesiophobia in subjects with onychocryptosis before and after surgery to eliminate this condition.
METHODS: A descriptive and observational study was conducted with a total sample size of 25 subjects with a mean age of 40.96 ± 18.25 years. The pretest sample was composed of the 25 subjects before the surgical treatment of onychocryptosis and the posttest sample was composed of the same 25 subjects after the surgical treatment of onychocryptosis. Kinesiophobia levels and total scores were self-reported using the Spanish version of the Tampa Scale for Kinesiophobia (TSK-11).
RESULTS: The Wilcoxon test for related samples and the Mann-Whitney U test for independent samples were used to compare the results before and after the surgical treatment. It was observed that in all the items as well as in the total score, there were significant changes in the levels of kinesiophobia, after the surgical intervention for onychocryptosis (P < 0.05) compared to the levels before surgery, except for items 4 and 11 in which there were no significant differences (P > 0.05). Before surgery, 0% of the subjects with onychocryptosis reported not being afraid of movement, 16% reported mild fear of movement, 8% reported moderate fear of movement and 76% of the subjects with onychocryptosis reported severe and maximum fear of movement. On the other hand, 100% of the subjects did not report kinesiophobia after surgical treatment (P < 0.01).
CONCLUSIONS: The levels of kinesiophobia were higher in the subjects with onychocryptosis compared to the subjects after having undergone surgery to eliminate onychocryptosis.
INTRODUCTION/AIMS: Limb-girdle muscular dystrophy R1 (LGMDR1) calpain 3-related usually presents as a recessively transmitted weakness of proximal limb-girdle muscles due to pathogenic variants in the CAPN3 gene. Pathogenic variants in this gene have also been found in patients with an autosomal dominantly inherited transmission pattern (LGMDD4). The mechanism underlying this difference in transmission patterns has not yet been elucidated. Camptocormia, progressive limb weakness, myalgia, back pain, and increased CK levels are common clinical features associated with dominant forms. The p.Lys254del pathogenic variant was associated with camptocormia in two LGMDD4 families. This study aimed to present carriers found in recessively transmitted LGMDR1 families bearing the p.Lys254del variant that do not show muscle weakness.
METHODS: DNA sequencing was performed on exon 5 of CAPN3 in family members to establish the carrier status of the pathogenic variant. They were evaluated clinically and MRI was performed when available.
RESULTS: Two families presented with the p.Lys254del pathogenic variant in a homozygous or compound heterozygous state. Family members carrying only the pathogenic variant in the heterozygous state did not demonstrate the myopathic characteristics described in dominant patients. Camptocormia and other severe clinical symptoms were not observed.
DISCUSSION: We conclude that the p.Lys254del pathogenic variant per se cannot be solely responsible for camptocormia in dominant patients. Other undisclosed factors may regulate the phenotype associated with the dominant inheritance pattern in CAPN3 pathogenic variant carriers.
FIELD: veterinary science. SUBSTANCE: the suggested method deals with introduction of medicinal preparation; additionally, one should introduce iodinated common salt, and metronidazole is used as medicinal preparation. Moreover, metronidazole and iodinated common salt should be introduced by courses once daily for 30 d at 6- mo-long intervals. Moreover, with prophylactic purpose introduction of metronidazole and iodinated common salt for cattle should be carried out since 6-mo-aged to 18-moaged period in the following dosages (g/animal): metronidazole 0.25, 0.5 and 1.0, iodinated common salt 30.0, 50.0 and 70.0; moreover, for 12-mo-aged animals one should additionally introduce sulfanilamide preparation in dosages of 0.5 and1.0 mg/animal, correspondingly. Moreover, with curative purpose metronidazole is introduced at the dosage of 1.0 g/animal, and iodinated common salt - at 70-90 g/animal, moreover, additionally, one should introduce sulfanilamide preparation at the dosage of 1.0 g/animal. Therapy course is repeated during 2 years. The present method is of high efficiency in treating and preventing cattle leukosis due to applying preparations of antibacterial action at the background of iodine deficiency elimination along prophylactic treatment of cattle youngsters for the purpose to heal the whole herd. EFFECT: higher efficiency. 3 cl, 2 tbl _
Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.